CR6165A - Procedimientos e intermedios para preparar compuestos anticancerosos - Google Patents

Procedimientos e intermedios para preparar compuestos anticancerosos

Info

Publication number
CR6165A
CR6165A CR6165A CR6165A CR6165A CR 6165 A CR6165 A CR 6165A CR 6165 A CR6165 A CR 6165A CR 6165 A CR6165 A CR 6165A CR 6165 A CR6165 A CR 6165A
Authority
CR
Costa Rica
Prior art keywords
intermediates
procedures
target compounds
prepare anti
compounds
Prior art date
Application number
CR6165A
Other languages
English (en)
Inventor
Shelton Lehner Richard
Paul Santafianos Dinos
Norris Timothy
Original Assignee
Pfizer Prod Inc
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Osi Pharm Inc filed Critical Pfizer Prod Inc
Publication of CR6165A publication Critical patent/CR6165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a procedimientos e intermedios para preparar compuestos de fórmula 1 y sales y solvatos farmacéuticamente aceptables de los mismos, así como compuestos estructuralmente relacionados, fórmula en la que R1, R2 y R15 son como se han definido en la Memoria. Los compuestos antes mencionados son útiles en el tratamiento de trastornos hiperproliferativos, así como cánceres, en mamíferos.
CR6165A 1999-03-31 2000-03-14 Procedimientos e intermedios para preparar compuestos anticancerosos CR6165A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
CR6165A true CR6165A (es) 2008-10-10

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6165A CR6165A (es) 1999-03-31 2000-03-14 Procedimientos e intermedios para preparar compuestos anticancerosos

Country Status (50)

Country Link
US (1) US6476040B1 (es)
EP (1) EP1044969B1 (es)
JP (2) JP3420549B2 (es)
KR (2) KR100430210B1 (es)
CN (2) CN1215061C (es)
AP (2) AP1655A (es)
AR (1) AR018705A1 (es)
AT (1) ATE348098T1 (es)
AU (2) AU781402B2 (es)
BG (1) BG65194B1 (es)
BR (1) BRPI0001486B8 (es)
CA (2) CA2302965C (es)
CO (1) CO5160273A1 (es)
CR (1) CR6165A (es)
CZ (1) CZ299426B6 (es)
DE (1) DE60032275T2 (es)
DK (1) DK1044969T3 (es)
DZ (1) DZ3030A1 (es)
EA (3) EA004654B1 (es)
EE (1) EE04589B1 (es)
EG (1) EG22506A (es)
ES (1) ES2278578T3 (es)
GE (1) GEP20022653B (es)
GT (1) GT200000037A (es)
HK (1) HK1029790A1 (es)
HR (1) HRP20000182B1 (es)
HU (1) HU227698B1 (es)
ID (1) ID25427A (es)
IL (2) IL135245A0 (es)
IS (1) IS2468B (es)
MA (1) MA25087A1 (es)
MY (1) MY136270A (es)
NO (2) NO321952B1 (es)
NZ (2) NZ512818A (es)
OA (1) OA11335A (es)
PA (1) PA8491901A1 (es)
PE (1) PE20001599A1 (es)
PL (1) PL339330A1 (es)
PT (1) PT1044969E (es)
RS (1) RS49836B (es)
SG (2) SG121687A1 (es)
SK (1) SK287339B6 (es)
SV (1) SV2002000047A (es)
TN (1) TNSN00064A1 (es)
TR (1) TR200000837A2 (es)
TW (1) TW553939B (es)
UA (2) UA80955C2 (es)
UY (1) UY26086A1 (es)
YU (1) YU13200A (es)
ZA (1) ZA200001586B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
SI1859793T1 (sl) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
US8349855B2 (en) * 2007-02-21 2013-01-08 Natco Pharma Limited Polymorphs of erlotinib hydrochloride and method of preparation
JP5524041B2 (ja) 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
EP2162444B1 (en) 2007-07-11 2014-06-04 Hetero Drugs Limited An improved process for the preparation of erlotinib hydrochloride
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
JP2011516426A (ja) * 2008-03-28 2011-05-26 コンサート ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体および治療方法
WO2010005924A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) * 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
ATE295839T1 (de) 1998-04-29 2005-06-15 Osi Pharm Inc N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat

Also Published As

Publication number Publication date
SK287339B6 (sk) 2010-07-07
AR018705A1 (es) 2001-11-28
AU2005201494B2 (en) 2008-02-07
AP1265A (en) 2004-03-26
SV2002000047A (es) 2002-01-23
CA2427221A1 (en) 2000-09-30
AP1655A (en) 2006-09-01
NZ503683A (en) 2001-09-28
HU227698B1 (en) 2011-12-28
CA2427221C (en) 2008-09-16
IL135245A0 (en) 2001-05-20
YU13200A (sh) 2002-10-18
EP1044969B1 (en) 2006-12-13
JP2000290262A (ja) 2000-10-17
HUP0001353A3 (en) 2002-01-28
CN1699350A (zh) 2005-11-23
IS2468B (is) 2008-12-15
NO20001648D0 (no) 2000-03-30
KR100430209B1 (ko) 2004-05-03
SG121687A1 (en) 2006-05-26
BG104278A (en) 2001-08-31
TR200000837A2 (tr) 2000-11-21
EA200000274A3 (ru) 2003-02-27
JP4074509B2 (ja) 2008-04-09
HK1029790A1 (en) 2001-04-12
KR20020084903A (ko) 2002-11-13
EA004654B1 (ru) 2004-06-24
ZA200001586B (en) 2001-10-01
TW553939B (en) 2003-09-21
KR20010014658A (ko) 2001-02-26
PL339330A1 (en) 2000-10-09
BR0001486A (pt) 2001-05-02
EA005892B1 (ru) 2005-06-30
OA11335A (en) 2003-12-10
NO321952B1 (no) 2006-07-24
CN100351242C (zh) 2007-11-28
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
EA200201245A1 (ru) 2003-04-24
GEP20022653B (en) 2002-03-25
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
AU781402B2 (en) 2005-05-19
EE04589B1 (et) 2006-02-15
KR100430210B1 (ko) 2004-05-03
EA005561B1 (ru) 2005-04-28
EE200000255A (et) 2000-12-15
NO20054715L (no) 2000-10-02
CZ299426B6 (cs) 2008-07-23
ATE348098T1 (de) 2007-01-15
PT1044969E (pt) 2007-05-31
EA200201244A1 (ru) 2003-04-24
PE20001599A1 (es) 2001-01-18
EA200000274A2 (ru) 2000-10-30
PA8491901A1 (es) 2001-12-14
ID25427A (id) 2000-10-05
DE60032275T2 (de) 2007-07-12
CA2302965C (en) 2004-02-17
BRPI0001486B1 (pt) 2019-01-29
JP2003176274A (ja) 2003-06-24
CZ20001155A3 (cs) 2001-03-14
IS5411A (is) 2000-10-02
UA70928C2 (uk) 2004-11-15
BG65194B1 (bg) 2007-06-29
SK4442000A3 (en) 2000-10-09
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
CN1215061C (zh) 2005-08-17
UA80955C2 (en) 2007-11-26
SG115536A1 (en) 2005-10-28
CN1276370A (zh) 2000-12-13
RS49836B (sr) 2008-08-07
UY26086A1 (es) 2000-10-31
NZ512818A (en) 2003-01-31
HRP20000182A2 (en) 2001-04-30
HUP0001353A2 (hu) 2001-05-28
AU2005201494A1 (en) 2005-05-05
MY136270A (en) 2008-09-30
EP1044969A3 (en) 2000-11-29
DE60032275D1 (de) 2007-01-25
DZ3030A1 (fr) 2004-03-27
NO20001648L (no) 2000-10-02
CO5160273A1 (es) 2002-05-30
CA2302965A1 (en) 2000-09-30
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
ES2278578T3 (es) 2007-08-16
GT200000037A (es) 2001-09-21
MA25087A1 (fr) 2000-10-01
BRPI0001486B8 (pt) 2021-05-25
JP3420549B2 (ja) 2003-06-23
DK1044969T3 (da) 2007-04-23
US6476040B1 (en) 2002-11-05
HU0001353D0 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
CR6165A (es) Procedimientos e intermedios para preparar compuestos anticancerosos
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
UY26872A1 (es) Derivados de la 4- fenil piridina
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
CR6643A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY26276A1 (es) 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164
PA8544901A1 (es) Derivados de oxazol
UY26782A1 (es) Derivados del benzotiazol
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
ES2161290T3 (es) Derivados de quinazolina.
UY28144A1 (es) Agentes terapéuticos
AR038045A1 (es) Agentes terapeuticos
UY29893A1 (es) Derivados de pirazina
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
UY28377A1 (es) Agentes terapeuticos
PA8589801A1 (es) Aminoalcoxiindoles
BR9911250A (pt) Processo para preparação de compostos
ECSP003410A (es) Procedimientos e intermedios para preparar compuestos anticancerosos